Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Shares Outstanding (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Shares Outstanding for 6 consecutive years, with $128.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding changed N/A year-over-year to $128.6 million, compared with a TTM value of $128.6 million through Dec 2025, changed N/A, and an annual FY2025 reading of $128.6 million, changed N/A over the prior year.
  • Shares Outstanding was $128.6 million for Q4 2025 at Cytek Biosciences, up from $127.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $136.3 million in Q2 2023 and bottomed at $31.8 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $121.7 million, with a median of $131.5 million recorded in 2024.
  • The sharpest move saw Shares Outstanding surged 363.52% in 2021, then dropped 4.26% in 2024.
  • Year by year, Shares Outstanding stood at $133.7 million in 2021, then grew by 1.21% to $135.4 million in 2022, then decreased by 3.44% to $130.7 million in 2023, then fell by 0.73% to $129.8 million in 2024, then decreased by 0.94% to $128.6 million in 2025.
  • Business Quant data shows Shares Outstanding for CTKB at $128.6 million in Q4 2025, $127.9 million in Q3 2025, and $127.2 million in Q2 2025.